Your browser doesn't support javascript.
loading
A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL.
Flinn, Ian W; Panayiotidis, Panayiotis; Afanasyev, Boris; Janssens, Ann; Grosicki, Sebastian; Homenda, Wojciech; Smolej, Lukas; Kuliczkowski, Kazimierz; Doubek, Michael; Domnikova, Natalia; West, Sarah L; Chang, Chai-Ni; Barker, Alison M; Gupta, Ira V; Wright, Oliver J; Offner, Fritz.
Afiliación
  • Flinn IW; Sarah Cannon Research Institute, Tennessee.
  • Panayiotidis P; Department of Propaedeutic Internal Medicine, Laiko Hospital, University of Athens, Athens, Greece.
  • Afanasyev B; Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, Pavlov State Medical University, St. Petersburg, Russian Federation.
  • Janssens A; Department of Development and Regeneration, Universitair Ziekenhuizen Leuven, Leuven, Belgium.
  • Grosicki S; Department of Cancer Prevention, School of Public Health, Silesian Medial University, Katowice, Poland.
  • Homenda W; Department of Hematology, Institute of Health Sciences Pomeranian Academy, Slupsk, Poland.
  • Smolej L; Department of Internal Medicine - Hematology, Faculty of Medicine in Hradec Kralove, University Hospital and Charles University in Prague, Hradec Kralove, Czech Republic.
  • Kuliczkowski K; Department and Clinic of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Akademia Medyczna We Wroclawiu, Wroclaw, Poland.
  • Doubek M; Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
  • Domnikova N; Department of Hematology, Novosibirsk State Regional Clinical Hospital, Novosibirsk, Russian Federation.
  • West SL; Global Clinical Development, Novartis, Uxbridge, United Kingdom.
  • Chang CN; Statistics, Novartis, Research Triangle Park, North Carolina.
  • Barker AM; Global Clinical Development, Novartis, Uxbridge, United Kingdom.
  • Gupta IV; Global Clinical Development, Novartis, King of Prussia, Pennnsylvania.
  • Wright OJ; Global Clinical Development, Novartis, Uxbridge, United Kingdom.
  • Offner F; Department of Internal Medicine, Universitair Ziekenhuis Gent, Gent, Belgium.
Am J Hematol ; 91(9): 900-6, 2016 09.
Article en En | MEDLINE | ID: mdl-27222473
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica / Clorhidrato de Bendamustina / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Hematol Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B / Protocolos de Quimioterapia Combinada Antineoplásica / Clorhidrato de Bendamustina / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Hematol Año: 2016 Tipo del documento: Article